4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Transthyretin amyloidosis (also known as ATTR amyloidosis) is a systemic, life-threatening disease characterized by transthyretin (TTR) fibril deposition in organs and tissue. A definitive diagnosis of ATTR amyloidosis is often a challenge, in large part because of its heterogeneous presentation. Although ATTR amyloidosis was previously considered untreatable, disease-modifying therapies for the treatment of this disease have recently become available. This article aims to raise awareness of the initial symptoms of ATTR amyloidosis among general practitioners to facilitate identification of a patient with suspicious signs and symptoms.

          Methods

          These consensus recommendations for the suspicion and diagnosis of ATTR amyloidosis were developed through a series of development and review cycles by an international working group comprising key amyloidosis specialists. This working group met to discuss the barriers to early and accurate diagnosis of ATTR amyloidosis and develop a consensus recommendation through a thorough search of the literature performed using PubMed Central.

          Results

          The cardiac and peripheral nervous systems are most frequently involved in ATTR amyloidosis; however, many patients often also experience gastrointestinal and other systemic manifestations. Given the multisystemic nature of symptoms, ATTR amyloidosis is often misdiagnosed as a more common disorder, leading to significant delays in the initiation of treatment. Although histologic evaluation has been the gold standard to confirm ATTR amyloidosis, a range of tools are available that can facilitate early and accurate diagnosis. Of importance, genetic testing should be considered early in the evaluation of a patient with unexplained peripheral neuropathy.

          Conclusions

          A diagnostic algorithm based on initial red flag symptoms and manifestations of cardiac or neurologic involvement will facilitate identification by the general practitioner of a patient with clinically suspicious symptoms, enabling subsequent referral of the patient to a multidisciplinary specialized medical center.

          Related collections

          Most cited references43

          • Record: found
          • Abstract: found
          • Article: found

          Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis

          Cardiomyopathy is a manifestation of transthyretin amyloid (ATTR) amyloidosis, which is an underrecognized systemic disease whereby the transthyretin protein misfolds to form fibrils that deposit in various tissues and organs. ATTR amyloidosis is debilitating and associated with poor life expectancy, especially in those with cardiac dysfunction, but a variety of treatment options have recently become available. Considered a rare disease, ATTR amyloidosis may be more prevalent than thought, particularly in older persons. Diagnosis is often delayed because of a lack of disease awareness and the heterogeneity of symptoms at presentation. Given the recent availability of effective treatments, early recognition and diagnosis are especially critical because treatment is likely more effective earlier in the disease course. The Amyloidosis Research Consortium recently convened a group of experts in ATTR amyloidosis who, through an iterative process, agreed on best practices for suspicion, diagnosis, and characterization of disease. This review describes these consensus recommendations for ATTR associated with cardiomyopathy (ATTR-CM) as a resource to aid cardiologists and others in the recognition and diagnosis of ATTR-CM. Included in this review is an overview of red flag signs and symptoms and a recommended diagnostic approach, including testing for monoclonal protein, scintigraphy, or biopsy and, if ATTR-CM is identified, TTR genotyping.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.

            Advances in cardiac imaging have resulted in greater recognition of cardiac amyloidosis in everyday clinical practice, but the diagnosis continues to be made in patients with late-stage disease, suggesting that more needs to be done to improve awareness of its clinical manifestations and the potential of therapeutic intervention to improve prognosis. Light chain cardiac amyloidosis, in particular, if recognized early and treated with targeted plasma cell therapy, can be managed very effectively. For patients with transthyretin amyloidosis, there are numerous therapies that are currently in late-phase clinical trials. In this review, we address common questions encountered in clinical practice regarding etiology, clinical presentation, diagnosis, and management of cardiac amyloidosis, focusing on recent important developments in cardiac imaging and biochemical diagnosis. The aim is to show how a systematic approach to the evaluation of suspected cardiac amyloidosis can impact the prognosis of patients in the modern era.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease

                Bookmark

                Author and article information

                Contributors
                gertz.morie@mayo.edu
                Journal
                BMC Fam Pract
                BMC Fam Pract
                BMC Family Practice
                BioMed Central (London )
                1471-2296
                23 September 2020
                23 September 2020
                2020
                : 21
                : 198
                Affiliations
                [1 ]GRID grid.66875.3a, ISNI 0000 0004 0459 167X, Mayo Clinic, ; 200 First Street SW, Rochester, MN 55905 USA
                [2 ]Referral Center for FAP, Neurology Department, APHP, INSERM U 1195, Université Paris-Sud, Le Kremlin Bicêtre, France
                [3 ]GRID grid.274841.c, ISNI 0000 0001 0660 6749, Department of Neurology, Graduate School of Medical Sciences, , Kumamoto University, ; Kumamoto, Japan
                [4 ]GRID grid.413438.9, ISNI 0000 0004 0574 5247, Ophthalmology Service, Hospital de Santo António, ; Porto, Portugal
                [5 ]GRID grid.239585.0, ISNI 0000 0001 2285 2675, Columbia University Medical Center, ; New York, NY USA
                [6 ]GRID grid.418340.a, ISNI 0000 0004 0392 7039, Centro Hospitalar do Porto, ; Porto, Portugal
                [7 ]GRID grid.67033.31, ISNI 0000 0000 8934 4045, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, ; Boston, MA USA
                [8 ]Department of Cardiology, Referral Center for Cardiac Amyloidosis, GRC Amyloid Research Institute, DHU A-TVB, APHP CHU Henri Mondor and Université Paris Est Créteil, Créteil, France
                [9 ]GRID grid.62560.37, ISNI 0000 0004 0378 8294, Brigham and Women’s Hospital, ; Boston, MA USA
                [10 ]GRID grid.25879.31, ISNI 0000 0004 1936 8972, University of Pennsylvania Perelman School of Medicine, ; Philadelphia, PA USA
                [11 ]GRID grid.83440.3b, ISNI 0000000121901201, National Amyloidosis Centre, University College London, ; London, UK
                [12 ]Amyloidosis Research Consortium, Newton, MA USA
                [13 ]GRID grid.7700.0, ISNI 0000 0001 2190 4373, University of Heidelberg, ; Heidelberg, Germany
                [14 ]GRID grid.239424.a, ISNI 0000 0001 2183 6745, Boston University School of Medicine, Boston Medical Center, ; Boston, MA USA
                [15 ]GRID grid.12650.30, ISNI 0000 0001 1034 3451, Department of Public Health and Clinical Medicine, , Umeå University, ; Umeå, Sweden
                [16 ]GRID grid.223827.e, ISNI 0000 0001 2193 0096, University of Utah Health, ; Salt Lake City, UT USA
                [17 ]GRID grid.6292.f, ISNI 0000 0004 1757 1758, University of Bologna, ; Bologna, Italy
                [18 ]GRID grid.168010.e, ISNI 0000000419368956, Stanford Amyloid Center, Stanford University School of Medicine, ; Stanford, California, USA
                [19 ]GRID grid.419425.f, ISNI 0000 0004 1760 3027, Amyloidosis Research and Treatment Center Foundation, IRCCS Policlinico San Matteo, ; San Matteo, Italy
                [20 ]GRID grid.8982.b, ISNI 0000 0004 1762 5736, Department of Molecular Medicine, , University of Pavia, ; Pavia, Italy
                Author information
                http://orcid.org/0000-0002-3853-5196
                Article
                1252
                10.1186/s12875-020-01252-4
                7513485
                32967612
                a6c03b47-419d-40d3-9285-3073066a9e92
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 11 March 2020
                : 25 August 2020
                Funding
                Funded by: Amyloidosis Research Consortium
                Categories
                Guidelines
                Custom metadata
                © The Author(s) 2020

                Medicine
                attr amyloidosis,attrv,diagnosis,hattr,polyneuropathy,cardiomyopathy,transthyretin amyloidosis
                Medicine
                attr amyloidosis, attrv, diagnosis, hattr, polyneuropathy, cardiomyopathy, transthyretin amyloidosis

                Comments

                Comment on this article